149 PROMIS in VWD, IPFDs and RBDs 5 INCLUSION CRITERIA Patients with von Willebrand disease were invited to participate if they met the following criteria: • Historically lowest VWF:Ag and/or VWF:RCo and/or VWF:CB ≤ 0.30 IU/mL and/or FVIII:C ≤ 0.40 IU/mL (type 2N) • Participated for two years in the Von Willebrand in the Netherlands – Prospective (WiN-Pro) study • Age ≥ 18 years old • Receives treatment at the hemophilia treatment center Erasmus MC, Erasmus University Medical Center, Rotterdam, the Netherlands Patients with an inherited platelet function disorder were invited to participate if they met the following criteria: • Participation in the Thrombocytopathy in the Netherlands (TiN) study and presence of permission to be contacted for follow-up studies • Patients with a confirmed congenital blood platelet disorders as defined by the TiN study; patients where an abnormal platelet function was found on at least two occasions, of which one was in diagnostics laboratory during the TiN study. • Age ≥ 18 years old Rare bleeding disorders (RBDs) were defined in the Rare Bleeding Disorder in the Netherlands (RBiN) study (2017-2019) as deficiencies of factor (F) II, FV, combined FV&FVIII, FVII, FX, FXI, FXIII, FV Amsterdam, and disorders of fibrinolysis: plasminogen activator type 1 (PAI-1) deficiency, alpha-2- antiplasmin (A2AP) deficiency, and hyperfibrinolysis. Patients with a RBD were invited to participate if they met the following criteria: • Participation in the RBiN study and presence of permission to be contacted for follow-up studies • Permission to use personal email address for study participation invitation via https://promis-symphony.nl/ • Age ≥ 18 years old • Receives treatment at the hemophilia treatment center NijmegenEindhoven-Maastricht, location Radboud university medical center, Radboud UMC, Nijmegen, the Netherlands.
RkJQdWJsaXNoZXIy MTk4NDMw